



In vitro and clinical validation of different correction algorithms for the two-dimensional proximal isovelocity surface area method in a low-velocity flow field for quantifying tricuspid regurgitation

Yu Liu^{1,2#}, Li Liu^{3#}, Beiqi Chen^{2,4}, Yuanfeng Wu^{2,4,5}, Rui Zhao⁶, Wuxu Zuo^{2,4}, Quan Li^{2,4}, Fangmin Meng^{1,2}, Dehong Kong^{2,4}, Cuizhen Pan^{2,4}, Lili Dong^{2,4}, Xianhong Shu^{2,4,5}

¹Shanghai Institute of Medical Imaging, Shanghai, China; ²Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai, China; ³National Institutes for Food and Drug Control, Beijing, China; ⁴Shanghai Institute of Cardiovascular Diseases, Shanghai, China; ⁵Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China; ⁶Department of Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA

Contributions: (I) Conception and design: Y Liu, L Liu; (II) Administrative support: L Liu, L Dong, X Shu; (III) Provision of study materials or patients: L Dong, X Shu; (IV) Collection and assembly of data: Y Liu, B Chen; (V) Data analysis and interpretation: W Zuo, Q Li, F Meng, D Kong, C Pan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Correspondence to: Lili Dong, MD, PhD. Department of Echocardiography, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai 200032, China; Shanghai Institute of Cardiovascular Diseases, Shanghai, China. Email: dong.lili@zs-hospital.sh.cn; Xianhong Shu, MD, PhD. Department of Cardiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai, China; Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Institute of Cardiovascular Diseases, Shanghai, China. Email: shu.xianhong@zs-hospital.sh.cn.

Background: The 2-dimensional proximal isovelocity surface area (2D PISA) method underestimates tricuspid regurgitation (TR) severity. Previously proposed correction algorithms should be further scrutinized.

Methods: Two correction algorithms were tested. One approach involves dividing the 2D PISA effective regurgitant orifice area by a constant of 0.7 ($EROA_{0.7}$). Another approach involves multiplying the unadjusted EROA by $V_{orifice}/(V_{orifice} - V_{aliasing})$, where $V_{orifice}$ denotes the TR jet velocity, and $V_{aliasing}$ represents the color aliasing velocity ($EROA_{V_0-V_a}$). *In vitro* validation was performed on a commercially available multifunctional valve tester with different size orifices and peak pressure gradients. A true EROA was derived through the regurgitant volume (RVol) calculated from the tester. For clinical validation, RVol was calculated as the difference between the overall stroke volume and the forward stroke volume of the right ventricle. Volumetric EROA was derived by dividing the RVol by the TR velocity-time integral (VTI). The vena contracta area (VCA) was obtained through direct planimetry with 3D echocardiography. The mean of volumetric EROA and VCA served as the reference in clinical validation.

Results: Excellent correlation between the calculated EROAs and the true EROA was observed *in vitro* ($r=0.98$, $r=0.97$, and $r=0.98$ for uncorrected EROA, $EROA_{V_0-V_a}$, and $EROA_{0.7}$, respectively; all P values <0.0001). $EROA_{V_0-V_a}$ underestimated the true EROA and averaged 33% ($P=0.3163$), while $EROA_{0.7}$ overestimated the true EROA and averaged 8% ($P=0.0032$). Clinically, these methods consistently exhibited a notable underestimation that varied with the reference EROA. This systematic underestimation was mitigated by both algorithms when either the VCA (biases of 19.6, 15.1, and 11.8 mm² for uncorrected EROA, $EROA_{V_0-V_a}$, and $EROA_{0.7}$, respectively) or the volumetric EROA (biases of 10.1, 5.6, and 2.3 mm² for uncorrected EROA, $EROA_{V_0-V_a}$, and $EROA_{0.7}$, respectively) served as the reference. Their ability to distinguish severe TR was similar, with area under the curve values of 0.905, 0.903, and 0.893 for uncorrected EROA, $EROA_{V_0-V_a}$, and $EROA_{0.7}$, respectively. No statistically significant differences were observed for

diagnostic accuracy (all P values >0.05).

Conclusions: Using a correction factor of 0.7 in quantifying TR provides similar accuracy when compared to other techniques. This represents a valuable clinical tool for quickly correcting the underestimation of the 2D PISA method in TR. This simple method may increase the frequency of applying the correction and earlier recognition of patients with severe TR.

Keywords: Tricuspid regurgitation (TR); proximal isovelocity surface area (PISA); 3D echocardiography; vena contracta area (VCA)

Submitted Nov 25, 2022. Accepted for publication Oct 11, 2023. Published online Nov 20, 2023.

doi: 10.21037/qims-22-1311

View this article at: <https://dx.doi.org/10.21037/qims-22-1311>

Introduction

Severe tricuspid regurgitation (TR) is associated with an increased mortality risk irrespective of pulmonary pressures and right ventricle (RV) dysfunction (1). However, these patients are often referred too late, and thus accurate severity grading may permit effective therapy at an earlier stage to improve survival (2). Current guidelines recommend a multiparametric approach that integrates qualitative, semiquantitative, and quantitative findings to estimate TR severity (3,4). The 2-dimensional proximal isovelocity surface area (2D PISA) method is the recommended approach for quantifying TR. This method relies on the accurate estimation of PISA, which is based on the measurement of its radius and subsequent calculation under the assumption of a hemispheric shape (*Figure 1A,1B*). However, previous *in vitro* studies demonstrated the hemispheric assumption is violated by variable regurgitant orifice and valve geometry (irregular PISA shape) as well as contour flattening (hemiellipsoid PISA shape) under low regurgitant velocities (5-10) (*Figure 1C-1E*), with the latter being the major source of error (11). Recent clinical studies comparing the 2D PISA method against other quantitative measurements also revealed significant underestimation of TR severity by 2D PISA (12,13).

Pilot studies proposed different algorithms to correct the underestimation caused by low peak regurgitant velocity (5,14) (*Figure 1*). For instance, Rodriguez *et al.* found that 2D PISA method progressively underestimated regurgitant flow when the velocity at PISA shell (V_{aliasing}) approached the peak velocity through the regurgitant orifice (V_{orifice}) and proposed to correct the effective regurgitant orifice area (EROA) through multiplying by $V_{\text{orifice}}/(V_{\text{orifice}} - V_{\text{aliasing}})$ (14). Deng *et al.* observed that when the pressure gradient was less than 40 mmHg, the effect of hemiellipsoid PISA shape

could no longer be adjusted through decreasing the V_{aliasing} but could be corrected empirically by dividing the EROA by a constant of 0.7 (5). However, these algorithms were proposed based on computational modeling and steady flow settings (constant flow rate through an orifice) and have yet to be validated either in pulsatile low-pressure models that mimic the flow environment of the right heart (changing instantaneous flow rate during every beat) or clinically for TR. The advantages and disadvantages of both the *in vitro* and *in vivo* methods are summarized in *Figure 2*. The *in vitro* method provides a gold standard reference but can only replicate a limited number of either flow conditions or valve geometry while the *in vivo* validation is valid for everyday clinical scenarios but does not have a universally-accepted reference standard.

Therefore, the aim of this study was (I) to examine the accuracy of different correction algorithms applied to the conventional 2D PISA method in pulsatile low-pressure models and (II) to compare the utility of these 2D PISA correction techniques to that of quantitative volumetric methods and vena contracta (VC) area in diagnosing severe TR.

Methods

In vitro validation

In vitro validation was performed on a multifunctional valve tester (PPD-1000, Shanghai Heartpartner Testing Equipment Co., Ltd., Shanghai, China) which consisted of a pulsatile bump, a ventricle chamber, a flow meter (transit-time ultrasonic flow probe, Transonic Systems, Inc., Ithaca, NY, USA) that measured the volume of fluid passing from the ventricle chamber into the arterial compliance module, the atrium chamber, and its compliance module (*Figure 3A*).

The circulatory fluid consisted of 30% glycerin, 70%




Figure 1 The conventional 2D PISA method and the proposed correction algorithms. Determination of the velocity of color aliasing and measurement of the PISA radius (A). Determination of the peak regurgitant jet velocity and calculation of the EROA (B). PISA contour at a color aliasing velocity of 0.11 m/s (C). PISA contour at a color aliasing velocity of 0.22 m/s (D). PISA contour at a color aliasing velocity of 0.32 m/s (E). PISA contour at a color aliasing velocity of 0.43 m/s (F). The lower panel of the figure shows the 2 proposed algorithms. Please refer to the text for a more detailed explanation. PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; UC, uncorrected; $V_{orifice}$, peak regurgitant velocity; $V_{aliasing}$, color aliasing velocity.




Figure 2 Advantages and disadvantages of the *in vitro* and *in vivo* methods. The orifice size and shape, the adjacent geometry, and the flow conditions can be controlled *in vitro*, but only limited conditions can be replicated, especially for the flow conditions due to the instability of the low-velocity flow field (upper left panel). The *in vitro* method provides a gold standard reference (upper right panel; refer to *Figure 3* for details). The *in vivo* validation represents everyday real clinical scenarios, such as a flail tricuspid leaflet (lower left panel). Neither the volumetric method nor the measurement of the vena contracta area is a gold standard reference for valve regurgitation quantification (lower right panel; refer to *Figures 4,5* for details). RVol, regurgitant volume; EROA, effective regurgitant orifice area; RVOT, right ventricular outflow tract; VTI, velocity-time index; SV, stroke volume; CSA, cross-section area; RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; TR, tricuspid regurgitation.




Figure 3 The *in vitro* validation. The *in vitro* validation model consisted of ① a pulsatile bump, ② the ventricle chamber, ③ the flow meter measuring the volume of fluid passing from the ventricle chamber into ④ the arterial compliance module, ⑤ the atrium chamber and its compliance module, ⑥ the control module of the bump, and ⑦ the control module of the flow meter (A). The VTI of the regurgitant jet was obtained from the continuous wave Doppler spectrum, from which the effective regurgitant orifice area could be calculated (B). RVol, regurgitant volume; SV, stroke volume; EROA, effective regurgitant orifice area; VTI, velocity-time integral.




Figure 4 Direct planimetry of the vena contracta area in a representative case. Two-dimensional and color Doppler imaging demonstrating a flail tricuspid leaflet (A). The 2 perpendicular longitudinal planes were aligned to match the color jet's orientation (B,C), and the transverse plane was shifted to the point where the cross-sectional area was minimized (D). The vena contracta could then be directly planimeted on the transverse plane.

water, and 1% corn starch added as ultrasound scattering particles in order to mimic the blood viscosity (15). Two millimeter-thick polytetrafluoroethylene plates with

different regurgitant orifice areas (20, 30, or 80 mm²) were placed between the atrium and ventricle module. All orifices were circular. The bump was controlled via a computer




Figure 5 Quantitation of TR severity through the volumetric method in a representative case. The diameter of the right ventricular outflow tract was measured from the parasternal short-axis view (A). The VTI was obtained from the pulsed-wave Doppler spectrum at the same level where the right ventricular outflow tract diameter was measured (B). The VTI of the tricuspid regurgitation jet was traced from the continuous wave Doppler spectrum (C). The right ventricular stroke volume was defined as the difference between end-diastolic volume and end-systolic volume and obtained using 3D echocardiography (D). The regurgitant volume and effective regurgitant orifice area could then be calculated. RVOT, right ventricular outflow tract; VTI, velocity-time integral; TR, tricuspid regurgitation; CSA, cross-section area; SV, stroke volume; RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVol, regurgitant volume; EROA, effective regurgitant orifice area.

that could adjust the speed and stroke length of the piston, which in turn determined the pressure wave form and stroke volume generated by the piston, respectively. The regurgitant volume (RVol) was defined as the difference between the stroke volume (SV) generated by the piston and the volume passing through the arterial end. The true EROA was calculated by dividing the RVol by the velocity-time integral (VTI) of the regurgitant jet as measured via continuous-wave (CW) Doppler (Figure 3B). The true EROAs acquired during three consecutive beats were averaged.

The heart rate was set to 72 beats per minute (a heart rate mimicking the normal human range was intended with lower heart rates being attempted, but it was difficult to maintain

a steady pulsatile flow without beat-to-beat variation under a low-pressure and low-pulse-frequency condition). The regurgitant stroke volume was controlled between 14 to 40 mL per beat (the stroke volume was arbitrarily adjusted to select volumes that could maintain stable piston operation), and the resultant peak pressure gradient ranged from 7 to 45 mmHg. Two-dimensional and Doppler echocardiographic examination of the *in vitro* model was performed using an Acuson SC2000 Prime (Siemens Healthineers, Erlangen, Germany) with a 4V1c probe.

Conventional 2D PISA method and correction under a low-regurgitant-pressure gradient

The baseline was shifted to 11, 22, 32 and 43 cm/s for PISA




Figure 6 Selection of the optimized PISA shell. The shape of PISA shell viewed under color Doppler imaging changed from oblate ellipsoid through sphere to prolate ellipsoid with decreasing color aliasing velocity both *in vitro* (A) and *in vivo* (B) settings. The PISA shell that was most representative of a round shape was chosen as the optimized one (in this case, aliasing velocity =0.11 m/s *in vitro* and aliasing velocity =0.25 m/s *in vivo*). V_{aliasing} , aliasing velocity; PISA, proximal isovelocity surface area.

measurement during 2D color Doppler echocardiography (CDE). An optimized PISA shell was defined as that most representative of a round shape (Figure 6).

Two previously described correction procedures were used to account for the contour flattening of the proximal flow convergence region under a low-regurgitant-pressure gradient (5,14) (Figure 1). One of these correction methods involves dividing the 2D PISA EROA by a factor of 0.7 and was referred to as $EROA_{0.7}$. The other method involves multiplying the unadjusted EROA by $V_{\text{orifice}}/(V_{\text{orifice}} - V_{\text{aliasing}})$, where V_{orifice} is the TR jet velocity, and V_{aliasing} is the color aliasing velocity ($EROA_{V_o-V_a}$); this method was referred to as $EROA_{V_o-V_a}$. Meanwhile, uncorrected EROAs were referred to as $EROA_{UC}$.

Clinical validation

For the clinical validation cohort, we enrolled 150 consecutive inpatients who were undergoing clinically indicated transthoracic echocardiography (TTE) for

elective cardiac surgery and who presented with more-than-mild TR at Zhongshan Hospital, Fudan University, from June of 2018 to December of 2019. The TTE session was routinely ordered the day before surgery at Zhongshan Hospital. Patients with any of the following conditions were not included in the study: intracardiac shunts, concomitant valvular lesions (more-than-mild pulmonary stenosis or pulmonary insufficiency), presence of a prosthetic tricuspid valve, incomplete visualization of the flow convergence region, and inadequate acoustic window (Figure S1). This study was approved by the ethics committee of Zhongshan Hospital, Fudan University, and conducted in accordance with the Declaration of Helsinki (as revised in 2013). Written consent was obtained from every patient.

Echocardiographic examination

A 2D and 3D transthoracic echocardiographic examination was performed on a commercially available ultrasound platform (Vivid E95, GE Healthcare, Chicago, IL, USA) with either a 2D or 3D probe as appropriate. Intraoperative

transesophageal echocardiography (TOE), which has better spatial resolution, is typically performed for every surgical patient as a clinical routine, but TOE was not employed as part of this study, as the time constraints on perioperative settings precluded the acquisition of a 3D dataset of the RV and 3D color Doppler images, which require fine tuning to achieve a balance between spatial and temporal resolution.

A minimum of six consecutive beats were collected to capture the complete respiratory cycle. Measurements were averaged from all the recorded images to eliminate the potential impact of respiratory variation and atrial fibrillation. The assessment of the TR mechanism involved the integration of findings from various cardiac structures, including the right atrium, tricuspid annulus, valve leaflets, subvalvular apparatus, and RV. The primary TR referred only to TR due to primary leaflet abnormality, as indicated in the regurgitation evaluation guidelines (3). Both image acquisition (Y.L. and B.C.) and analysis (Y.L. and Y.W.) were performed by experienced cardiologists.

2D echocardiography

2D echocardiography was performed according to the current guidelines (16). The baseline was shifted to 18 to 40 cm/s for PISA measurement during 2D CDE to achieve an optimized PISA shell most representative of a round shape (Figure 6). VC width was obtained from the apical 4-chamber view (A4C). For jet area or PISA radius measurement, additional views were assessed to optimize the visualization of the jet or to align the sample line with the flow. Angle correction for 2D PISA was applied as per the relevant guidelines (3), and low-regurgitant-velocity correction was calculated as *in vitro* model.

3D echocardiography

3D volumes were acquired from the RV-focused A4C. The patient was positioned in the steep left lateral orientation. Sector size and depth were fine-tuned to encompass the complete RV while a volume rate of 20 to 25 volumes per second was maintained. The dataset was exported for subsequent analysis with dedicated software (4D RV-Function 2.0; TomTec Imaging Systems, Unterschleissheim, Germany) to obtain the RV end-diastolic volume (RVEDV), RV end-systolic volume (RVESV), and RV SV.

The 3D VC area (VCA) was acquired and measured as previously described with minimal color gain (−4 dB, 10–20%) (17). Specifically, the frame closest to the time of peak velocity on CW spectral display was chosen in order to achieve concomitant timing with 2D PISA measurement.

The two perpendicular longitudinal planes were aligned to match the color jet's orientation, and the transverse plane was shifted to the point where the cross-sectional area was minimized. The VCA could then be directly planimetered on the transverse plane (Figure 4).

Reference standard

TR was graded using the guideline-recommended integral approach (3). Specific criteria for mild TR included (I) a thin and small central color jet; (II) a VC width less than 0.3 cm from A4C; (III) a PISA radius less than 0.4 cm at Nyquist 30–40 cm/s; (IV) incomplete or faint CW Doppler jet spectrum; (V) systolic dominant hepatic vein flow; (VI) tricuspid A-wave-dominant inflow, and (VII) a normal RV and right atrium (RA). Criteria for severe TR included (I) dilated annulus with no valve coaptation or flail leaflet; (II) large central jet occupying more than 50% of the RA; (III) a VC width greater than 0.7 cm from A4C; (IV) a PISA radius greater than 0.9 cm at Nyquist 30–40 cm/s; (V) a dense and triangular CW jet or sine wave pattern; (VI) systolic reversal of hepatic vein flow, and (VII) a dilated RV with preserved function. If four or more of the specific criteria were met, TR was graded mild or severe. If fewer than four of the criteria or contradictory measurement values were present, quantitative measurements would be performed including (I) averaged VC width taken from A4C and the RV inflow view with cutoffs of 0.3 and 0.7 cm, respectively; (II) direct-planimetered VCA with cutoffs of 0.2 and 0.4 cm²; and (III) RVol calculated through the volumetric approach with cutoffs of 30 and 45 mL. The severity was determined based on the majority of the three quantitative parameters. The severity grading was performed by Y.L., B.C. and L.D. at least 2 months before comprehensive 2D PISA calculation, with these observers being blinded to the grades when the index 2D PISA parameters were measured.

VCA and volumetric RVol, respectively, were chosen to substitute for EROA and RVol by conventional 2D PISA as recommended by the current guidelines, as the 2D PISA method was the method being evaluated.

The volumetric approach calculated the tricuspid RVol by subtracting the right ventricular outflow tract (RVOT) forward SV from the RV SV (Figure 5). The RVOT SV was calculated as the result of multiplying the cross-sectional area with the VTI of the RVOT. Both the RVOT diameter and the VTI were measured at the pulmonary valve annulus from the parasternal short-axis view on a midsystolic frame. The RV SV was calculated as the difference between the RV EDV and RV ESV, both of which were obtained from 3D

echocardiography as described above. The volumetric EROA was then calculated as RVol divided by the VTI of TR. The reference EROA in multilinear regression analysis was calculated as the mean of the VCA and volumetric EROA.

Statistical analysis

The Kolmogorov-Smirnov test for normality was performed on all data sets. Continuous data are expressed as the mean \pm standard deviation (SD) or as median (interquartile range) according to data distribution, and categorical data are presented using percentages and frequencies. Continuous data of the baseline characteristics were compared using analysis of variance (ANOVA) with Geisser-Greenhouse correction, post hoc comparisons were made using Dunn-Šidák correction, and frequencies were compared using the chi-squared test. EROAs of different correction algorithms were compared using simple linear regression, and the agreement was tested using Bland-Altman analysis directly or after logarithmic transformation depending on the data distribution. The correlations were reported using the Pearson correlation coefficient (r). Multivariable linear regression analysis was performed to identify the factors associated with the underestimation of conventional 2D PISA method, which was defined as the difference between the reference EROA and that of the uncorrected 2D PISA. Candidate independent variables were selected based on previous studies [systolic pulmonary artery pressure, $V_{\text{orifice}}/(V_{\text{orifice}} - V_{\text{aliasing}})$] (5,14), clinical considerations in valve regurgitation quantitation (etiology, atrial fibrillation), and the theoretical hydrodynamic model of PISA [reference EROA, RVEDV, the ratio of reference EROA to RVEDV (reference EROA/RVEDV)]. These three candidate types were specifically included because the proximal flow convergence zone would interfere with the ventricle and invalidate the hemispheric assumption when the regurgitant orifice was sufficiently large to approach the ventricular wall. These candidates were entered into the multivariable regression model simultaneously, and the final model excluded the reference EROA due to its colinearity with reference EROA/RVEDV. The units used for per-unit changes in the model were mmHg for RV systolic pressure, mm^2 for reference EROA and the dependent variable, and mL for RVEDV. Receiver operating characteristic (ROC) curve analysis was used to determine the grading accuracy of the quantitative parameters. The maximal Youden index (sensitivity + specificity - 1) was used to define the best cutoffs in ROC analysis. 2D PISA-derived

EROA, volumetric EROA, and VCA measurements from 10 patients were repeatedly acquired by the same observer (Y.L.) and a different observer (Y.W.) to determine intra- and interobserver variability. Patients were chosen randomly for this test. Both investigators possess specialized expertise in quantifying TR and were unaware of each other's findings. The repeated measurements were conducted no less than 3 months after the initial measurements were taken.

All statistical tests were 2-tailed, and P values <0.05 were considered to indicate statistical significance. Statistical analysis was performed using GraphPad Prism version 9.4 (GraphPad Software, San Diego, CA, USA) and SPSS version 26.0 (IBM Corp., Armonk, NY, USA).

Results

In vitro model

Figure 7 shows the calculated EROA, either corrected or not, plotted against the true EROA for the three circular orifices (0.20, 0.30, and 0.80 cm^2) at various aliasing velocities (0.11, 0.22, 0.32, and 0.43 cm/s). There was good correlation between the calculated EROAs and the true EROA ($r=0.85$, $r=0.88$, and $r=0.85$ for EROA_{UC} , $\text{EROA}_{\text{V}_0\text{-V}_a}$, and $\text{EROA}_{0.7}$, respectively; all P values <0.0001). However, EROA_{UC} and $\text{EROA}_{\text{V}_0\text{-V}_a}$ demonstrated significant underestimation of the true EROA (both P values <0.0001 , Friedman test), while $\text{EROA}_{0.7}$ only slightly underestimated the true EROA. Both correction algorithms lessened the magnitude of underestimation and narrowed the limits of agreement compared with the true EROA (Figure 7C-7E).

Figure 8 illustrates the relationship between the calculated EROAs and the true EROA after aliasing velocity optimization (when the proximal flow convergence zone was most representative of a round shape). As the optimization involved one measurement under a certain aliasing velocity over the other three (chosen from 11, 22, 32, and 43 cm/s), the sample size was one-fourth of that presented in Figure 7. The mean and SD of the selected optimized aliasing velocities were 24 and 7 cm/s , respectively. The correlation became better ($r=0.98$, $r=0.97$, and $r=0.98$ for EROA_{UC} , $\text{EROA}_{\text{V}_0\text{-V}_a}$, and $\text{EROA}_{0.7}$, respectively; all P values <0.0001), and $\text{EROA}_{\text{V}_0\text{-V}_a}$ only produced an underestimation mean of 0.02 cm^2 compared with the true EROA (P=0.3163, 1-way ANOVA), while $\text{EROA}_{0.7}$ overestimated the true EROA with a mean bias of 0.05 cm^2 (P=0.0032, 1-way ANOVA) (Figure 8).




Figure 7 Comparison of the calculated EROAs and the true EROA *in vitro*. Friedman test (A). Simple linear regression (B). Bland-Altman analysis (C-E). ns, $P > 0.05$; ****, $P \leq 0.0001$. ROA, regurgitant orifice area; EROA, effective regurgitant orifice area; UC, uncorrected; V_0 , peak regurgitant velocity; V_a , color aliasing velocity; LoA, limit of agreement.

Clinical validation

Patient characteristics

Initially, 150 patients were screened, but 10 were excluded due to incomplete 3D images of the RV, 8 due to a poor acoustic window, and 1 due to severe pulmonary regurgitation. Ultimately, 131 patients were successfully enrolled and studied. Patients' baseline characteristics and 2D and 3D echocardiographic parameters are shown in *Table 1*. Among the whole patient population and among those with severe TR, 59.8% and 73.2% were receiving diuretics, respectively.

Comparison of the correction algorithms for the 2D PISA method with the reference methods

The EROAs calculated through 2D PISA method, either corrected or not, correlated well with both the VCA ($r=0.74$, $r=0.73$, and $r=0.70$ for $EROA_{UC}$, $EROA_{V_0-V_a}$, and $EROA_{0.7}$, respectively; P values < 0.0001 ; *Figure 9*) and volumetric EROA ($r=0.75$, $r=0.74$, and $r=0.72$ for $EROA_{UC}$, $EROA_{V_0-V_a}$, and $EROA_{0.7}$, respectively; all P values < 0.0001 ; *Figure 10*).

However, a consistent significant underestimation by the 2D PISA methods was observed as a function of the EROA in both functional and primary TR. Both correction algorithms lessened the systematic underestimation (*Figures 11,12, Tables 2,3*), but the limits of agreement remained relatively unchanged. It was also observed that the differences between methods were more sparsely distributed and skewed upward as the EROA increased, which suggested that the underestimation by the 2D PISA methods proportionally increased and that the agreement between methods became worse in larger EROAs in both functional and primary TR.

Table 4 shows the multilinear regression model, in which the dependent variable was defined as the difference between the uncorrected 2D PISA EROA and the reference EROA (the mean of the VCA and volumetric EROA). It was demonstrated that the aliasing velocity-related correction coefficient, $V_{\text{orifice}} / (V_{\text{orifice}} - V_{\text{aliasing}})$, the RVEDV, and the ratio between the reference EROA and RVEDV contributed significantly to the difference between the uncorrected 2D PISA EROA and the reference EROA.




Figure 8 Comparison of the calculated EROAs and the true EROA with an optimized baseline shift. One-way analysis of variance (A). Simple linear regression (B). Bland-Altman analysis (C-E). ns, $P > 0.05$; *, $P \leq 0.05$; **, $P \leq 0.01$. ROA, regurgitant orifice area; EROA, effective regurgitant orifice area; UC, uncorrected; Vo, peak regurgitant velocity; Va, color aliasing velocity; LoA, limit of agreement.

Comparison of severity grading accuracy

In ROC analysis, the accuracies of the 2D PISA methods for differentiating severe TR, as defined using the guideline-recommended integral approach, were similar [area under the curve (AUC): 0.905, 0.903, and 0.893 for $EROA_{UC}$, $EROA_{Vo-Va}$, and $EROA_{0.7}$, respectively]. No significant differences were found regarding diagnostic accuracy (all P values > 0.05 , Z test). The cutoff values for severe TR in $EROA_{UC}$, $EROA_{Vo-Va}$, and $EROA_{0.7}$ were 0.26 (83.3% and 84.4% for sensitivity and specificity, respectively), 0.29 (83.3% and 84.4% for sensitivity and specificity, respectively), and 0.39 cm^2 (72.2% and 93.5% for sensitivity and specificity, respectively), respectively, as defined by the Youden index. The cutoff values for severe TR stratified by etiology are provided in [Table S1](#).

Intra- and interobserver agreement

The intra- and interobserver repeatability was good for 2D PISA EROA and was modest for volumetric EROA as the confidence intervals were wider ([Table S2](#)). The intraobserver agreement was good for VCA, but the interobserver agreement of this parameter was only fair as

indicated by the very wide CIs.

Discussion

Current guidelines recommend the use of the 2D PISA method to quantify TR and note the possibility of underestimation (3), which has been substantiated by recent studies (12,13). However, no correction algorithm is recommended for TR, and the different correction methodologies applied across studies have yielded markedly divergent partition values (12,18-20). Computational modeling demonstrates that the effect of low regurgitant velocity accounts for the majority of 2D PISA error (11). Therefore, in this study, we evaluated different correction algorithms, specifically regurgitant-orifice-to-Nyquist-velocity ratio correction and the constant 0.7 correction for low regurgitant velocity both in pulsatile models and in clinic. Our principal findings were as follows: (I) Aliasing velocity optimization combined with the proposed correction factor, $V_{\text{orifice}} / (V_{\text{orifice}} - V_{\text{aliasing}})$, could effectively account for the systematic underestimation by the 2D PISA method under low-regurgitant-velocity conditions

Table 1 Baseline characteristics and 2D and 3D echocardiographic parameters stratified by etiology and regurgitant severity

Variable	Primary TR		Functional TR		P
	Nonsevere (n=13)	Severe (n=24)	Nonsevere (n=64)	Severe (n=30)	
Age (years)	61±15	60±11	61±11	62±10	0.931
Gender, male	7 (54%)	8 (33%)	21 (33%)	10 (33%)	0.535
BSA (m ²)	1.51±0.19	1.53±0.16	1.55±0.15	1.60±0.19	0.224
Heart rate (bpm)	80±14	76±14	85±18	80±15	0.096
Atrial fibrillation	9 (69%)	14 (58%)	41 (64%)	23 (77%)	0.516
CI (mL/min/m ²)	2.09±0.75	2.06±0.76	1.85±0.54	1.94±0.60	0.427
sPAP (mmHg)	43±14	37±11	43±16	41±16	0.386
TR VTI (cm)	86.6±20.5	74.9±19.2	86.6±23.0	81.9±18.9	0.149
2DE quantitative parameters					
VCW (mm)	5.5±1.4	8.1±2.3	4.1±1.2	7.5±2.3	<0.001*
2D PISA EROA (mm ²)	19.9±7.9	51.6±22.7	16.6±9.0	40.3±17.6	<0.001*
3DE quantitative parameters					
RVEF (%)	53±11	54±10	50±10	55±9	0.134
RVEDV (mL)	128±42	173±56	107±33	147±40	<0.001*
RVESV (mL)	63±33	83±40	54±21	67±24	<0.001*
VCA (mm ²)	48.2±37.1	87.1±39.0	23.1±13.2	71.2±31.0	<0.001*
Volumetric EROA (mm ²)	31.4±13.6	71.3±30.7	22.0±14.2	52.2±22.4	<0.001*

*, P value <0.05. Data are presented as mean ± standard deviation and n (%). TR, tricuspid regurgitation; BSA, body surface area; CI, cardiac index; sPAP, systolic pulmonary arterial pressure; VTI, velocity-time integral; 2DE, 2-dimensional echocardiography; VCW, vena contracta width; PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; 3DE, 3-dimensional echocardiography; RVEF, right ventricular ejection fraction; RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; VCA, vena contracta area.




Figure 9 Correlation between the calculated 2D PISA EROAs and VCA in patients with TR. PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; VCA, vena contracta area; TR, tricuspid regurgitation; UC, uncorrected; Vo, peak regurgitant velocity; Va, color aliasing velocity.




Figure 10 Correlation between the calculated 2D PISA EROAs and volumetric EROA in patients with TR. PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; TR, tricuspid regurgitation; UC, uncorrected; V_0 , peak regurgitant velocity; V_a , color aliasing velocity.




Figure 11 Bland-Altman analysis between the calculated 2D PISA EROAs and VCA in patients with TR stratified by etiology. Green lines represent bias, and blue dotted lines represent the limits of agreement. For the values of bias and limits of agreement, refer to *Table 2*. PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; VCA, vena contracta area; TR, tricuspid regurgitation; UC, uncorrected; V_0 , peak regurgitant velocity; V_a , color aliasing velocity; FTR, functional tricuspid regurgitation; PTR, primary tricuspid regurgitation.




Figure 12 Bland-Altman analysis between the calculated 2D PISA EROAs and volumetric EROA in patients with TR stratified by etiology. Green lines represent bias, and blue dotted lines represent the limits of agreement. For the values of bias and limits of agreement, refer to Table 3. PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; TR, tricuspid regurgitation; UC, uncorrected; Vo, peak regurgitant velocity; Va, color aliasing velocity; FTR, functional tricuspid regurgitation; PTR, primary tricuspid regurgitation.

Table 2 Bias (limits of agreement) from the Bland-Altman analysis between the calculated 2D PISA EROAs and VCA in patients with TR stratified by etiology

TR etiology	EROA _{UC}	EROA _{0.7}	EROA _{Vo-Va}
All TR	20 (-21 to 70)	12 (-41 to 64)	15 (-35 to 65)
Primary TR	33 (-28 to 94)	21 (-45 to 86)	27 (-36 to 89)
Functional TR	14 (-28 to 56)	8 (-37 to 53)	11 (-32 to 53)

PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; VCA, vena contracta area; TR, tricuspid regurgitation; UC, uncorrected; Vo, peak regurgitant velocity; Va, color aliasing velocity.

Table 3 Bias (limits of agreement) from the Bland-Altman analysis between the calculated 2D PISA EROAs and volumetric EROA in patients with TR stratified by etiology

TR etiology	EROA _{UC}	EROA _{0.7}	EROA _{Vo-Va}
All TR	10 (-26 to 46)	2 (-38 to 43)	6 (-32 to 43)
Primary TR	17 (-24 to 58)	4 (-47 to 56)	10 (-33 to 54)
Functional TR	7 (-25 to 40)	1 (-34 to 37)	4 (-30 to 38)

PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; TR, tricuspid regurgitation; UC, uncorrected; Vo, peak regurgitant velocity; Va, color aliasing velocity.

in vitro, which confirms the accuracy of the correction when other sources of error are controlled. (II) After the $V_{\text{orifice}}/(V_{\text{orifice}} - V_{\text{aliasing}})$ correction, there remained significant underestimation by 2D PISA EROA clinically, which

is concordant with previous studies demonstrating that irregular orifice and varied valve geometry also contribute to the error of 2D PISA method. (III) A constant correction coefficient of 0.7 demonstrated high accuracy in diagnosing

Table 4 Multilinear regression analysis with the dependent variable defined as the difference between the uncorrected 2D PISA EROA and the reference EROA

Variable	Unstandardized B	Standardized coefficients beta	t	VIF	P value
Etiology	1.628	0.040	0.6184	1.330	0.5374
Atrial fibrillation	0.7791	0.020	0.3559	1.012	0.7225
RVEDV	0.1569	0.401	6.723	1.152	<0.0001*
sPAP	-0.1176	-0.095	1.157	2.180	0.2496
Aliasing correction coefficient	-113.7	-0.277	3.409	2.144	0.0009*
Reference EROA/RVEDV	63.94	0.591	9.658	1.213	<0.0001*

*, P value <0.05. PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; VIF, variance inflation factor; RVEDV, right ventricular end-diastolic volume; sPAP, systolic pulmonary artery pressure.

severe TR and good agreement with the reference values in clinic. (IV) The absolute size of the EROA and the relative size of the EROA to the RV cavity contributed significantly to the measurement error by 2D PISA method.

The 2D PISA method is based on the hydrodynamic theory which predicts that flow approaches a point-like (infinitesimal) orifice in a flat plate as a series of concentric hemispheric shells of decreasing area and increasing velocity (14). The radius of the shell can be measured to calculate the area of the proximal isovelocity contour based on the hemispheric assumption, and quantitative regurgitant indices can then be derived by the conservation of mass. However, in clinical practice, the prerequisite for the hydrodynamic assumption is often violated. The regurgitant orifice of TR is irregular and larger rather than point-like (orifice shaped) (21), the tricuspid valve is tethered rather than flat (global geometry) (22), and the peak regurgitant velocity is comparatively low rather than almost infinitely large through a point-like orifice (low-velocity flow field), all of which lead to the distortion of the true PISA; thus, the PISA calculated by measuring the radius of the proximal isovelocity contour shell could result in over- or underestimation; the first problem above is addressed in the guidelines of the American Society of Echocardiography developed in collaboration with Society for Cardiovascular Magnetic Resonance, with different cutoffs for severe primary and secondary mitral regurgitation, and the second is addressed via an angle-correction algorithm (3). However, the effect of a low-velocity flow field has only been studied by computational and *in vitro* modeling, and while different correction algorithms have been proposed, they have not been clinically validated, and guideline recommendations do not yet exist.

Our study confirmed that aliasing velocity optimization

combined with the proposed correction factor, $V_{\text{orifice}}/(V_{\text{orifice}} - V_{\text{aliasing}})$, could account for the systematic underestimation by 2D PISA method under low-pressure conditions *in vitro*, where no other sources of error exist. The 0.7-constant correction overestimates EROA *in vitro* but shows only marginal systematic bias clinically. This could be explained by its overestimation compensating for other sources of underestimation that were not accounted for in our study. Importantly, the underestimation under low-pressure conditions has been reported to be the major source of error in 2D PISA method, with the underestimation via irregular orifice shape being comparatively marginal (10). On the other hand, as is evidenced by the cutoffs stratified by etiology, with the same reference standard, the cutoffs for functional TR were generally smaller than for primary TR. These findings suggest that 2D PISA tends to underestimate EROA to a greater extent in functional TR than in primary TR, which could be explained as a result of PISA underestimation due to the effect of ellipsoidal regurgitant orifice shape in functional TR (23). This can also be attributed to the limited sample size in the current study. As constant correction provided similar accuracy compared to conventional PISA method with decreased systematic bias, it may be a clinically useful means to quickly estimate TR severity but should be further validated in a larger cohort with balanced etiological groups.

Another important finding of the current study is that the absolute size of the EROA and the relative size of the EROA to the RV cavity contribute significantly to the measurement error of 2D PISA method. This could be explained by the violation of the theoretical assumption of the flow convergence method and the difficulty in determining the regurgitant orifice. Proximal flow convergence method requires a regurgitant orifice present

on an infinitely large plane so that the flow accelerates toward the orifice in a predictable manner. However, when a baseline shift is performed at low regurgitant velocities in TR, the aliasing border usually interacts with the ventricular wall before an optimized hemispherical shell of PISA can be obtained. This has been demonstrated in previous studies, which reported that confining wall geometry strained the streamline distribution in the proximal flow field (24,25). Moreover, one previous study indicated that the major source of inconsistency in PISA measurement is the inability to determine the center point of the regurgitant orifice, which is located much farther from either the leaflet tip or the outer margin of VC in the presence of extremely severe TR. This could add to the variability of PISA radius measurement.

Future technical improvements

3D CDE can directly measure the PISA shell without geometric assumptions and is expected to overcome the limitations of the 2D PISA method (26). It has been validated in a group of patients with functional TR and demonstrated improved agreement with the reference method compared with the 2D PISA method (13). However, several problems need to be addressed before wider clinical application of the 3D PISA method. First, 3D PISA is not the actual PISA but the proximal iso-Doppler-velocity surface area (27-30), and this could lead to underestimation. In addition, the limited temporal resolution of 3D CDE makes it hard to select the convergence zone that actually coincides with the peak regurgitant velocity, and thus may cause overestimation of the EROA with the clinically used peak PISA method. Finally, the current 3D PISA method is based on a proprietary vendor platform and software package, which further limits its widespread adoption.

Clinical implications

Quantitative assessment of the severity of TR remains challenging. The 2D PISA method is recommended to quantify TR, but the application of this approach requires the orifice radius to be infinitesimal compared with the PISA radius, which is often hard to achieve with low regurgitant velocities and leads to significant underestimation of TR severity. Two correction proposed algorithms, the regurgitant-orifice-to-Nyquist-velocity ratio correction and the constant 0.7 correction, were tested in this study. The former excellently corrects the error caused by low

regurgitant velocities *in vitro* but still requires correction for other sources of error including valve geometry (angle correction) and irregular orifice when applied clinically; meanwhile, the latter overestimates EROA *in vitro* but shows good agreement with the reference method and high accuracy in determining severe TR in clinical validation. This represents a valuable clinical tool for quick correction of the underestimation by 2D-the PISA method in TR.

Limitations

Choice of disperse orifice sizes

The plates with orifices were prepared using perforating cutting dies, with the available sizes included being 20, 30, and 80 mm² and larger or smaller ones. Smaller or larger sizes would either be subject to manufacturing error or change the boundary condition on which PISA method relies. A more granular scale of orifice size would better mimic the clinical scenarios.

Reference standard

As external reference standards for TR quantification are limited, several comparator methods were used in this study, each of which may involve measurement variability (31,32). For VCA, although the temporal resolution of 3D CDE on modern echocardiography machines is not lower than that of 2D CDE, it comes at the price of spatial resolution. The use of VCA as a reference method is thus subject to the error of spatial averaging. TOE was not employed in this study but may provide better definition of VCA with its high spatial resolution.

In the volumetric approach, there is no validation of the RV volume against cardiac magnetic resonance (CMR), and the measurement of RVOT diameter from a 2D perspective might lead to either an over- or underestimation of the RVOT area. A preliminary study comparing CMR-derived RVol to that derived by 3DE also showed slight underestimation (3.6 mL) (32).

Intermodality comparison

CMR is also the recommended modality for quantifying TR and has been increasingly adopted in recent studies (31,33). The reference methods of our study are echocardiography-based and thus were unable to provide information on intermodality agreement, which may significantly affect clinical decision-making. Future studies are expected to validate these proposed PISA correction algorithms against CMR imaging.

Effect of temporal variation

The PISA method is based on single-frame measurements. Previous experience in mitral regurgitation shows that temporal variation of regurgitant flow and orifice area during systole could lead to clinically significant underestimation by the PISA method (34,35). Preliminary evidence has also emerged suggesting the existence of dynamic systolic flow in TR (36), which was not accounted for in the current study. Future studies are expected to validate the existence of temporal variation in TR and its effect on PISA accuracy.

Vendor dependency

For either *in vitro* or *in vivo* validation, only 1 ultrasound machine vendor was used. As color Doppler imaging is sensitive to technical settings and as different vendors adopt different rendering strategies and smoothing algorithms, the PISA method might be subject to vendor dependency. The comparison made in this study was based on the same vendor and could still be considered valid; however, the cutoffs reported may not be directly applicable in clinical use or comparison in future studies.

The atrial and ventricular type of functional TR

The atrial and ventricular type of functional TR are associated with different patterns of valve deformation geometry (22,37) and may thus behave differently when the 2D PISA method is applied. However, as most of our patients had a disease origin of the left heart and only concomitantly had atrial fibrillation and as paroxysmal atrial fibrillation was not excluded, it was impossible to differentiate between the atrial or ventricular type of functional TR in this study. Subsequent studies with strict patient selection protocols and a larger sample size to investigate the impact of such subgroups are needed.

Unaccounted sources of error in 2D PISA

Complex valve geometry and variable regurgitant orifice shape were not accounted for in this study. 2D PISA quantification with an extremely eccentric jet is highly challenging, as it would be hard to align the insonation beam for the recording of the Doppler spectrum while the proximal flow field may be largely distorted from the hemispheric assumption. The simple constant correction only provides a tool to avoid underestimation of TR severity. Approaches to addressing all possible sources of error and accurately quantifying valve regurgitation should be developed.

Conclusions

Using a correction factor of 0.7 in quantifying TR provides similar accuracy to that of the conventional method and the complex aliasing velocity-based correction method. This approach lessens the systematic underestimation of the conventional 2D PISA method in a low-velocity flow field in TR compared with other quantitative approaches. This represents a valuable clinical tool for quickly correcting the underestimation of the 2D PISA method in TR and may increase the frequency of applying the correction and earlier recognition of patients with severe TR.

Acknowledgments

We would like to thank all the patients who participated in this study and the engineers from Siemens for their technical assistance. Part of the abstract has been presented during a moderated poster session at the 2023 Congress of the European Society of Cardiology.

Funding: This work was supported by the National Natural Science Foundation of China (Nos. 81771837 and 82227803), the Shanghai Committee of Science and Technology (No. 17411962400) and the Shanghai Municipal Key Clinical Specialty (No. shslczdzk03501).

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://qims.amegroups.com/article/view/10.21037/qims-22-1311/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and was approved by the ethics committee of Zhongshan Hospital, Fudan University. Informed consent was obtained from all individual participants.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the

original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Wang N, Fulcher J, Abeysuriya N, McGrady M, Wilcox I, Celermajer D, Lal S. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. *Eur Heart J* 2019;40:476-84.
2. Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, Caranhac G, Messika-Zeitoun D. Timing of Referral of Patients With Severe Isolated Tricuspid Valve Regurgitation to Surgeons (from a French Nationwide Database). *Am J Cardiol* 2018;122:323-6.
3. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S, Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. *J Am Soc Echocardiogr* 2017;30:303-71.
4. Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, Hagendorff A, Monin JL, Badano L, Zamorano JL; European Association of Echocardiography. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). *Eur J Echocardiogr* 2010;11:307-32.
5. Deng YB, Shiota T, Shandas R, Zhang J, Sahn DJ. Determination of the most appropriate velocity threshold for applying hemispheric flow convergence equations to calculate flow rate: selected according to the transorifice pressure gradient. Digital computer analysis of the Doppler color flow convergence region. *Circulation* 1993;88:1699-708.
6. Rodriguez L, Thomas JD, Monterroso V, Weyman AE, Harrigan P, Mueller LN, Levine RA. Validation of the proximal flow convergence method. Calculation of orifice area in patients with mitral stenosis. *Circulation* 1993;88:1157-65.
7. Shandas R, Gharib M, Sahn DJ. Nature of flow acceleration into a finite-sized orifice: steady and pulsatile flow studies on the flow convergence region using simultaneous ultrasound Doppler flow mapping and laser Doppler velocimetry. *J Am Coll Cardiol* 1995;25:1199-212.
8. Barclay SA, Eidenvall L, Karlsson M, Andersson G, Xiong C, Ask P, Loyd D, Wranne B. The shape of the proximal isovelocity surface area varies with regurgitant orifice size and distance from orifice: computer simulation and model experiments with color M-mode technique. *J Am Soc Echocardiogr* 1993;6:433-45.
9. Anayiotos AS, Perry GJ, Myers JG, Green DW, Fan PH, Nanda NC. A numerical and experimental investigation of the flow acceleration region proximal to an orifice. *Ultrasound Med Biol* 1995;21:501-16.
10. Lee J, Mitter SS, Van Assche L, Huh H, Wagner GJ, Wu E, Barker AJ, Markl M, Thomas JD. Impact of assuming a circular orifice on flow error through elliptical regurgitant orifices: computational fluid dynamics and in vitro analysis of proximal flow convergence. *Int J Cardiovasc Imaging* 2023;39:307-18.
11. Lee J, Mitter SS, Van Assche L, Huh H, Wagner GJ, Wu E, Barker AJ, Markl M, Thomas JD. Impact of assuming a circular orifice on flow error through elliptical regurgitant orifices: computational fluid dynamics and in vitro analysis of proximal flow convergence. *Int J Cardiovasc Imaging* 2023;39:307-18.
12. Dahou A, Ong G, Hamid N, Avenatti E, Yao J, Hahn RT. Quantifying Tricuspid Regurgitation Severity: A Comparison of Proximal Isovelocity Surface Area and Novel Quantitative Doppler Methods. *JACC Cardiovasc Imaging* 2019;12:560-2.
13. de Agustin JA, Viliani D, Vieira C, Islas F, Marcos-Alberca P, Gomez de Diego JJ, Nuñez-Gil IJ, Almeria C, Rodrigo JL, Luaces M, Garcia-Fernandez MA, Macaya C, Perez de Isla L. Proximal isovelocity surface area by single-beat three-dimensional color Doppler echocardiography applied for tricuspid regurgitation quantification. *J Am Soc Echocardiogr* 2013;26:1063-72.
14. Rodriguez L, Anconina J, Flachskampf FA, Weyman AE, Levine RA, Thomas JD. Impact of finite orifice size on proximal flow convergence. Implications for Doppler quantification of valvular regurgitation. *Circ Res* 1992;70:923-30.
15. Little SH, Igo SR, McCulloch M, Hartley CJ, Nosé Y, Zoghbi WA. Three-dimensional ultrasound imaging model of mitral valve regurgitation: design and evaluation. *Ultrasound Med Biol* 2008;34:647-54.
16. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in

- Adults: Recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr* 2019;32:1-64.
17. Liu Y, Chen B, Zhang Y, Zuo W, Li Q, Jin L, Kong D, Pan C, Dong L, Shu X, Ge J. Sources of Variability in Vena Contracta Area Measurement for Tricuspid Regurgitation Severity Grading: Comparison of Technical Settings and Vendors. *J Am Soc Echocardiogr* 2021;34:270-278.e1.
 18. Bartko PE, Arfsten H, Frey MK, Heitzinger G, Pavo N, Cho A, Neuhold S, Tan TC, Strunk G, Hengstenberg C, Hülsmann M, Goliash G. Natural History of Functional Tricuspid Regurgitation: Implications of Quantitative Doppler Assessment. *JACC Cardiovasc Imaging* 2019;12:389-97.
 19. Peri Y, Sadeh B, Sherez C, Hochstadt A, Biner S, Aviram G, Ingbir M, Nachmany I, Topaz G, Flint N, Keren G, Topilsky Y. Quantitative assessment of effective regurgitant orifice: impact on risk stratification, and cut-off for severe and torrential tricuspid regurgitation grade. *Eur Heart J Cardiovasc Imaging* 2020;21:768-76.
 20. Muraru D, Previtero M, Ochoa-Jimenez RC, Guta AC, Figliozzi S, Gregori D, Bottigliengo D, Parati G, Badano LP. Prognostic validation of partition values for quantitative parameters to grade functional tricuspid regurgitation severity by conventional echocardiography. *Eur Heart J Cardiovasc Imaging* 2021;22:155-65.
 21. Song JM, Jang MK, Choi YS, Kim YJ, Min SY, Kim DH, Kang DH, Song JK. The vena contracta in functional tricuspid regurgitation: a real-time three-dimensional color Doppler echocardiography study. *J Am Soc Echocardiogr* 2011;24:663-70.
 22. Topilsky Y, Khanna A, Le Tourneau T, Park S, Michelena H, Suri R, Mahoney DW, Enriquez-Sarano M. Clinical context and mechanism of functional tricuspid regurgitation in patients with and without pulmonary hypertension. *Circ Cardiovasc Imaging* 2012;5:314-23.
 23. Song JM, Kim MJ, Kim YJ, Kang SH, Kim JJ, Kang DH, Song JK. Three-dimensional characteristics of functional mitral regurgitation in patients with severe left ventricular dysfunction: a real-time three-dimensional colour Doppler echocardiography study. *Heart* 2008;94:590-6.
 24. Anayiotos AS, Fan P, Perry GJ, Myers J, Elmahdi AM, Nanda NC. Analysis of the Proximal Orifice Flowfield Under Pulsatile Flow Conditions and Confining Wall Geometry: Implications in Valvular Regurgitation. *Echocardiography* 1998;15:219-32.
 25. Pu M, Vandervoort PM, Greenberg NL, Powell KA, Griffin BP, Thomas JD. Impact of wall constraint on velocity distribution in proximal flow convergence zone. Implications for color Doppler quantification of mitral regurgitation. *J Am Coll Cardiol* 1996;27:706-13.
 26. Thavendirathan P, Liu S, Datta S, Rajagopalan S, Ryan T, Igo SR, Jackson MS, Little SH, De Michelis N, Vannan MA. Quantification of chronic functional mitral regurgitation by automated 3-dimensional peak and integrated proximal isovelocity surface area and stroke volume techniques using real-time 3-dimensional volume color Doppler echocardiography: in vitro and clinical validation. *Circ Cardiovasc Imaging* 2013;6:125-33.
 27. Little SH, Igo SR, Pirat B, McCulloch M, Hartley CJ, Nosé Y, Zoghbi WA. In vitro validation of real-time three-dimensional color Doppler echocardiography for direct measurement of proximal isovelocity surface area in mitral regurgitation. *Am J Cardiol* 2007;99:1440-7.
 28. Little SH. Is it really getting easier to assess mitral regurgitation using the proximal isovelocity surface area? *J Am Soc Echocardiogr* 2012;25:824-6.
 29. Badano LP, Hahn R, Rodríguez-Zanella H, Araiza Garaygordobil D, Ochoa-Jimenez RC, Muraru D. Morphological Assessment of the Tricuspid Apparatus and Grading Regurgitation Severity in Patients With Functional Tricuspid Regurgitation: Thinking Outside the Box. *JACC Cardiovasc Imaging* 2019;12:652-64.
 30. deGroot C, Drangova M, Fenster A, Zhu S, Pflugfelder PW, Boughner DR. Evaluation of 3-D colour Doppler ultrasound for the measurement of proximal isovelocity surface area. *Ultrasound Med Biol* 2000;26:989-99.
 31. Zhan Y, Debs D, Khan MA, Nguyen DT, Graviss EA, Khalaf S, Little SH, Reardon MJ, Nagueh S, Quiñones MA, Kleiman N, Zoghbi WA, Shah DJ. Natural History of Functional Tricuspid Regurgitation Quantified by Cardiovascular Magnetic Resonance. *J Am Coll Cardiol* 2020;76:1291-301.
 32. Utsunomiya H, Harada Y, Susawa H, Takahari K, Ueda Y, Izumi K, Itakura K, Ikenaga H, Hidaka T, Fukuda Y, Shiota T, Kihara Y. Comprehensive Evaluation of Tricuspid Regurgitation Location and Severity Using Vena Contracta Analysis: A Color Doppler Three-Dimensional Transesophageal Echocardiographic Study. *J Am Soc Echocardiogr* 2019;32:1526-1537.e2.
 33. Zhan Y, Senapati A, Vejpongsa P, Xu J, Shah DJ, Nagueh SF. Comparison of Echocardiographic Assessment of Tricuspid Regurgitation Against Cardiovascular Magnetic Resonance. *JACC Cardiovasc Imaging* 2020;13:1461-71.
 34. Uretsky S, Aldaia L, Marcoff L, Koulogiannis K, Hiramatsu S, Argulian E, Rosenthal M, Gillam LD, Wolff SD. The Effect of Systolic Variation of Mitral

- Regurgitation on Discordance Between Noninvasive Imaging Modalities. *JACC Cardiovasc Imaging* 2019;12:2431-42.
35. Hung J, Otsuji Y, Handschumacher MD, Schwammenthal E, Levine RA. Mechanism of dynamic regurgitant orifice area variation in functional mitral regurgitation: physiologic insights from the proximal flow convergence technique. *J Am Coll Cardiol* 1999;33:538-45.
36. Li L, Colen TM, Jani V, Barnes BT, Craft M, Tham E, Khoo NS, Smallhorn J, Danford DA, Kutty S. Dynamic Systolic Changes in Tricuspid Regurgitation Vena Contracta Size and Proximal Isovelocity Surface Area in Hypoplastic Left Heart Syndrome: A Three-Dimensional Color Doppler Echocardiographic Study. *J Am Soc Echocardiogr* 2021;34:877-86.
37. Utsunomiya H, Itabashi Y, Mihara H, Berdejo J, Kobayashi S, Siegel RJ, Shiota T. Functional Tricuspid Regurgitation Caused by Chronic Atrial Fibrillation: A Real-Time 3-Dimensional Transesophageal Echocardiography Study. *Circ Cardiovasc Imaging* 2017;10:e004897.

Cite this article as: Liu Y, Liu L, Chen B, Wu Y, Zhao R, Zuo W, Li Q, Meng F, Kong D, Pan C, Dong L, Shu X. *In vitro* and clinical validation of different correction algorithms for the two-dimensional proximal isovelocity surface area method in a low-velocity flow field for quantifying tricuspid regurgitation. *Quant Imaging Med Surg* 2024;14(1):160-178. doi: 10.21037/qims-22-1311




Figure S1 Study flowchart. TR, tricuspid regurgitation; RV, right ventricle; PISA, proximal isovelocity surface area; VCA, vena contracta area; ICD, intracardiac device; TV, tricuspid valve; LHD, left-heart disease; PH pulmonary hypertension; AF, atrial fibrillation.

Table S1 The 2D PISA EROA cutoffs for severe TR by different algorithms and stratified by etiology

Etiology	EROA _{UC} , cm ² (sensitivity, specificity)	EROA _{0.7} , cm ² (sensitivity, specificity)	EROA _{Vo-Va} , cm ² (sensitivity, specificity)
All TR	0.26 (83.3%, 84.4%)	0.39 (72.2%, 93.5%)	0.29 (83.3%, 84.4%)
Primary TR	0.26 (91.7%, 92.3%)	0.33 (87.5%, 84.6%)	0.29 (91.7%, 92.3%)
Functional TR	0.23 (86.7%, 78.1%)	0.28 (83.9%, 78.1%)	0.24 (90.3%, 75.0%)

PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; TR, tricuspid regurgitation; UC, uncorrected; Vo, peak regurgitant velocity; Va, color aliasing velocity.

Table S2 Intra- and interobserver measurement errors for standard 2D PISA EROA, volumetric EROA, and VCA

Error	2D PISA EROA	Volumetric EROA	VCA
Intraobserver measurement error ICC (95% CI)	0.95 (0.84 to 0.99)	0.83 (0.55 to 0.95)	0.93 (0.76 to 0.98)
Interobserver measurement error ICC (95% CI)	0.91 (0.69 to 0.98)	0.84 (0.46 to 0.95)	0.76 (0.30 to 0.94)

PISA, proximal isovelocity surface area; EROA, effective regurgitant orifice area; VCA, vena contracta area; ICC, intraclass coefficient; 95% CI, 95% confidence interval.